All In Biotech

Drug Trial Radar · NCT02826486

Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients

A Phase IIa, Multicenter, Open-label Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Patients With Metastatic Pancreatic Cancer, the COMBAT Study (KEYNOTE-202)

Last checked: Nov 19, 2026Latest source record: Aug 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

80

Actual

Start

Sep 2016

Primary completion

Sep 6, 2022

Study completion Sep 6, 2022

Sponsor

Lead sponsor
BioLineRx, Ltd.Industry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Jul 11, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the efficacy and safety of BL-8040 in combination with pembrolizumab (Keytruda®) and BL-8040/ Pembrolizumab in combination with liposomal irinotecan (Onivyde®)/5-fluorouracil/leucovorin (5-FU/LV) in subjects with metastatic pancreatic adenocarcinoma.

Conditions

  • Metastatic Pancreatic Adenocarcinoma

Interventions

  • BL-8040Drug

    BL-8040 subcutaneous (SC) injections

  • PembrolizumabDrug

    Pembrolizumab will be given as a 30-minute IV infusion

  • ChemotherapyDrug

    • IV Onivyde® followed by IV leucovorin (LV), followed by IV fluorouracil (5-FU), every 2 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) Assessed by Imaging According to RECIST 1.1 CriteriaTime frame: Change in response between screening, end of monotherapy (Day 5), end of cycle 2 (Day 28) and approximately every 63 days until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.

Locations

31 sites in 4 countries. Site status is shown where the registry gives one.

  • Mayo Clinic

    Phoenix, Arizona

  • Honor Health

    Scottsdale, Arizona

  • Ochsner Medical Center

    New Orleans, Louisiana

  • Massachusetts General Hospital (MGH)

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center (BIDMAC)

    Boston, Massachusetts

  • DF/HCC

    Boston, Massachusetts

  • Karmanos Cancer Center, Wayne State University

    Detroit, Michigan

  • Washington University of St Louis

    St Louis, Missouri

  • Atlantic Medical Group

    Morristown, New Jersey

  • NYU Langone Health

    New York, New York

  • Cornell Medical College

    New York, New York

  • University of Rochester

    Rochester, New York

  • Baylor Charles A. Sammons Cancer Center

    Dallas, Texas

  • Virginia Mason Medical Center

    Seattle, Washington

  • Rambam Medical Center

    Haifa, Israel

  • Shaare Zedek Medical Center

    Jerusalem, Israel

  • Rabin Medical Center

    Petah Tikva, Israel

  • Chaim Sheba Medical Center

    Ramat Gan, Israel

  • Sourasky Medical Center

    Tel Aviv, Israel

  • Samsung Medical Center

    Seoul, South Korea

  • Hospital General Universitario de Elche

    Alicante, Spain

  • Vall d'Hebron

    Barcelona, Spain

  • Gregorio Marañón Hospital

    Madrid, Spain

  • Hospital Universitario de Fuenlabrada

    Madrid, Spain

  • Hospital Universitario Ramón y Cajal

    Madrid, Spain

  • La Paz

    Madrid, Spain

  • Hospitalario Universitario de Ourense

    Ourense, Spain

  • Clinic Universidad de Navarra

    Pamplona, Spain

  • University Hospital of Salamanca

    Salamanca, Spain

  • Marques de Valdecilla de Santander

    Santander, Spain

  • Hospital Universitari i Politècnic La Fe,

    Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.